OHIO DEPARTMENT OF MEDICAID
Pharmacy & Therapeutics Committee

Public attendees will need to register at:
https://attendee.gotowebinar.com/register/702258497457130254

After registering, you will receive an email containing information about joining the webinar.

April 6th, 2022
10:00 A.M.

AGENDA

I. Call to Order
II. Introductions
III. Approval of January 12, 2022 Meeting Minutes
IV. Administrative Matters
V. Department of Medicaid Updates
VI. Manufacturer Presentations
VII. Interested Party Presentations
VIII. Preferred Drug List (PDL) Proposals
   A. Analgesic Agents: NSAIDs
      • Elyxyb (celecoxib solution), Dr. Reddy's Laboratories, Inc.
   B. Central Nervous System (CNS) Agents: Anticonvulsants
      • Eprontia (topiramate solution), Azurity Pharmaceuticals, Inc.
   C. Endocrine Agents: Growth Hormone
      • Skynulo (lonapegsomatropin-tcdg injection), Ascendis Pharma, Inc.
      • Criteria administrative reorganization
   D. Ophthalmic Agents: Dry Eye Treatments
      • Tyrva (varenicline tartrate nasal spray), Oyster Point Pharma.
IX. Drug Class Announcements
   A. Dermatologic Agents: Oral Retinoids
X. Other Business
   A. Cardiovascular Agents: Lipotropics
   B. Central Nervous System (CNS) Agents: Anti-Migraine Agents, Prophylaxis
   C. Central Nervous System (CNS) Agents: Medication Assisted Treatment of Opioid Addiction
   D. Respiratory Agents: Monoclonal Antibodies-Anti-IL/Anti-IgE
XI. 2022 Meeting Dates
   A. Quarter 3 – Wednesday, July 13, 2022
   B. Quarter 4 – Wednesday, September 28, 2022
XII. Adjournment

The Ohio Department of Medicaid (ODM) is committed to providing access and inclusion and reasonable accommodation in its services, activities, programs, and employment opportunities in accordance with the Americans with Disabilities Act (ADA) and other applicable laws. To request a reasonable accommodation due to a disability, please contact ODM’s ADA Coordinator at 614-995-9981/TTY 711, Fax 1-614-644-1434, or Email: ODM_EEO_EmployeeRelations@medicaid.ohio.gov at least three (3) business days prior to the scheduled meeting. Further information can be found here: Notice of Nondiscrimination.